- Breast
cancer is the leading cancer diagnosed in women, with more than two
million new cases diagnosed this year
- BriaCell
Therapeutics advancing prospects of its trademarked Bria-IMT immunotherapy
treatment for breast cancer in phase I/IIa trial
- Company
presented data from ongoing trial during San Antonio Breast Cancer
Symposium, one of the largest breast cancer conferences in the world
The holidays can be a particularly poignant time for
receiving a cancer diagnosis as all of society celebrates a season of cheer and
shares goodwill with each other, but the San Antonio Breast Cancer Symposium
(SABCS), one of the largest breast cancer conferences in the world, and
participants such as BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT),
shared a gift of knowledge about breast cancer this month through presentations
on the latest science in the fight against it and the avenues of hope for those
who have been diagnosed with it.
BriaCell Therapeutics counts among the more than 7,000
physicians and researchers from more than 90 countries who gathered for the
five-day conference that began December 4 to allow professionals opportunities
to connect with each other, learn about developments and obtain continuing
education credit. BriaCell presented information on its trademarked Bria-IMT
immunotherapy technology, which has shown promise as a monotherapy and still
greater potential in combination with a renowned protein-inhibiting antibody
recognized for its ability to manipulate a patient’s own immune system to fight
cancer.
“Bria-IMT has demonstrated positive proof-of-concept in
advanced breast cancer patients, and we will delve into these data in San
Antonio,” CEO Dr. Bill Williams stated in a news release about the
conference (http://ibn.fm/q7tAf). “We
have firm grounds to believe the anti-tumor effects of Bria-IMT can be greatly
improved by combination with pembrolizumab [KEYTRUDA®; manufactured by Merck
& Co., Inc. (NYSE: MRK)]. We are excited with the early clinical findings
of this novel treatment approach and look forward to presenting our data.”
The December 6 conference poster session presentation showed
safety and efficacy results of BriaCell’s phase I/IIa targeted immunotherapy
trial in patients with advanced breast cancer, as well as the early safety data
of the combination study of Bria-IMT™ with KEYTRUDA®. KEYTRUDA® targets protein
PD-1, which can block immune system cells from fighting off tumor cells.
KEYTRUDA® attempts to “release the brakes” set in place by PD-1 and let the
immune system do its work. BriaCell believes that the combination of Bria-IMT™
with KEYTRUDA® will be much more effective in killing the tumor cells compared
with using either of the drugs alone.
“There’s mini-symposia that are sort of small, more thematic
meetings that are going to cover several areas like immunotherapy in breast
cancer” SABCS co-director C. Kent Osborne noted in a video (http://ibn.fm/ffWdD), “It’s been
proven to be effective in certain other tumors; it’s just getting started in
breast cancer, so that will be a major part of our conference this year.”
“What is discussed at the SABCS truly guides what is studied
in the field of breast cancer all over the world,” another co-director, Dr.
Virginia Kaklamani of the University of Texas Health San Antonio breast cancer
program, told the San Antonio Business Journal (http://ibn.fm/eqS80). “The
physicians and scientists take what they learn here back to their practices or
labs the following Monday morning to improve care for patients.”
BriaCell’s aim is to produce personalized, off-the-shelf
medication to match patients’ needs without the time, expense and complex
manufacturing logistics associated with other personalized immunotherapies, and
to do so with fewer side effects than currently approved personalized
immunotherapies.
More than two million new cases of breast cancer have been
diagnosed this year, making it the most commonly occurring cancer in women and
the second most common cancer overall, according to the World Cancer Research
Fund International (http://ibn.fm/tzVSy).
There is tremendous need for new treatment options for advanced breast cancer.
For more information, visit the company’s website at www.BriaCell.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment